TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total number of days on Orencia therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in time to complete 3km time trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Disease Activity Score 28 (DAS28-ESR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HUTT positivity rate during passive phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HUTT positivity rate during active phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with at least 50% reduction in number of therapeutic paracenteses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined rate of open surgical reintervention due to pump system related adverse event or to restore pump functionality, pump explant due to pump system related adverse event, or pump system related death
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of downstaging to resectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum tolerated dose of expanded NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of accidental enteral probes exit per patient
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of PTSD severity (CAPS severity score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in associated psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in associated biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum level menaquinone-7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of prostatic cells collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) for sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of circulating adipokines levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of homeostasis model assessment (HOMA-β)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of area under the curve (AUC2h) of C-peptide during a mixed meal tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of M value evaluated by the euglycemic hyperinsulinemic clamp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in quality of life between the first and second trimester
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in percentage posterior migration of the humeral head
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Insulin Secretion Rate AUC Percent Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: urinary albumin excretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Response to Controlled Ovarian Hyperstimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Weeks continuous abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall treatment outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in HbA1c [percent]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects in remission (HAMD-17 score ≤ 7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Upper Extremity Fugl-Meyer (UEFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pubertal Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cancer Incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients experiencing new gouty arthritis flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of patients who reached clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Body Mass Index Percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Long-term safety of CIS administration
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in the health-related outcome measurement instruments (ODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in the health-related outcome measurement instruments (COMI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in the health-related outcome measurement instruments (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: First Episode of Confirmed Vaccine-type Community-acquired Pneumonia (VT-CAP)
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of patients in major molecular response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment-free survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Activity Measure (PAM-13) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes from baseline in Medical Outcomes Study Short-Form 12 (MOS-SF-12v2) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes from baseline in Autosomal Dominant Polycystic Kidney Disease-Impact Scale (ADPKD-IS) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes from baseline in ADPKD - Pain & Discomfort Scale (ADPKD-PDS) score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Signs of toxicity associated with vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: high-sensitivity C-Reactive Protein (hsCRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in cardiovascular risk score (Framingham score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number and type of cardiovascular events
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve From Zero to Last Time (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in P. aeruginosa density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of congenital haemophilia A and B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Severity of congenital haemophilia A and B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes from baseline for clinical laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline for vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness measured by exercise testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ICU survival
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of a suicidal event
Endpoint domain: Adverse events/effects
Primary endpoint: 24 Hour Measured Caloric Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Days Requiring Transfusions or Grade 4 Thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: sensitivity and specificity of PET/CT tracers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of confirmed diagnoses for child abuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impaired endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in the Postural Tremor Score of the Target Limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With Device-related or Procedure Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Total volume of fluid given
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of pressor use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean best corrected visual acuity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NSAA scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 Meter Walk/ Run test (10MW/RT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 Minutes Walk Test (6 MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children who achieved spasm freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight of sputum expectorated during airway clearance therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Weight of sputum expectorated 24 hours post bronchial session
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Major congenital malformations (MCMs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Change of Tissue Factor Bearing Microparticles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of febrile infectious episodes diagnosed
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who are retained in treatment for at least 60 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants who graduate from court
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants who are abstinent from opioid use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who recidivate within 12 months following court completion
Endpoint domain: Adverse events/effects
Primary endpoint: 3-year PFS
Endpoint domain: Mortality/survival
Primary endpoint: Mean minimum plaque pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of ALI or ARDS
Endpoint domain: Adverse events/effects
Primary endpoint: Number of fatal and non-fatal events
Endpoint domain: Mortality/survival
Primary endpoint: ASAS 20/40/50/70
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASAS 5/6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing threshold level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of hearing - adults
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Auditory development - children (CAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total calories ordered for child in restaurant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total saturated fat ordered for child in restaurant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total sugar ordered for child in restaurant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of Plasma DF 2156Y
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of Plasma DF 2156Y
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Narcotics / Morphine Milligram Equivalents (MME) given
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Control of Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Functional Assessment of Cancer Therapy-Fatigue (FACT-F) scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in 6 minute walk test (6MWT) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of tooth loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of CCSVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in excretion and supersaturation of urine calcium oxalate / phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ultrasound detectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Assessment of the elbow module
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Assessment of the hand module
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Successful completion of tasks (without intervention)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Successful completion of tasks (with intervention)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proper Use of PCC Proportion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area Under the Curve (AUCt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hours (AUC[0-8h]) of Vemurafenib on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Vemurafenib on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Plasma Concentration (Tmax) of Vemurafenib on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Benzodiazepine doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ObsQoR-11 validation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: cccDNA rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic yield of AIP patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause 90-day Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in GABA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in glutamate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post meal tolerance test glycemic excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of intraoperative pulmonary embolism (PE)
Endpoint domain: Adverse events/effects
Primary endpoint: Receipt of influenza vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Evidence Based Practice Confidence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Evidence Based Practice Behavior
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Participants with Demonstrated Benefit in Global Measures
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants with Demonstrated Benefit in Cognitive Measures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Success of articaine buccal infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of carotid vulnerable plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose of ABT-888
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consistency of care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of Catheter-related Bloodstream Infections (CRBSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Daily Medication Compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rescue Inhaler Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Presence of itching for more than 1 week
Endpoint domain: Adverse events/effects
Primary endpoint: Variation of the minimum luminal area (MLA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent change in LDL cholesterol from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of participants with grade 3-4 neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety parameters and adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Hematology and clinical chemistry changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters (AUC, Cmax, etc.)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin lifting capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of colorectal cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: maintenance of weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in decision making on technical resectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Blood ng/dL Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With An Abnormal Safety Lab (CBC)
Endpoint domain: Adverse events/effects
Primary endpoint: 5-year Cumulative hepatocellular carcinoma incidence
Endpoint domain: Mortality/survival
Primary endpoint: Temperature of the tonsils
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Hospital Behaviour Questionnaire (PHBQ) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SDQ Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pelvic Recurrence-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: occurrence of post-operative complication grade ≥ 2
Endpoint domain: Adverse events/effects
Primary endpoint: Picky eating behavior at age 3
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevention of urinary tract infection (UTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient compliance with utilizing home telehealth monitoring equipment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Home telehealth case management time utilized
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Oxytocin receptor expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Orthostatic Hypotension Questionnaire (OHQ) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PDQ-39 Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of patients with HIV-RNA levels < 50 c/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical validated quit rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participants satisfaction with Health Care Provider (HCP) training
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average Percent Difference in Area Between Visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Percent Difference in Area Between Raters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Prostate-Specific Antigen (PSA) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Freedom from Clinically driven TLR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: DDT & DDE pesticide levels in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximal platelet aggregation (MPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Pulmonary Function Test (PFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Asthma Control Test (ACT) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentual difference in Annexin A5 targeting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Brief Pain Inventory Q3 Worst Pain Score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: rate of smoking cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes